Preclinical phase

Phase i

Phase ii a

Phase ii b

Phase iii



Type 2 Diabetes

SER140 is a potent interleukin-1 (IL-1) receptor antagonist.

SER140 targets patients as early as possible after they have been diagnosed with Type 2 Diabetes.

In 10 major markets (US, major 5 in EU, Japan, China, India and Brazil) the prevalent diabetic population is approximately 190 million people of which 120 million are treated. The pharmaceutical market in 2012 was more than $ 28 billion with projected sales in 2022 of $68 billion.

1.   SER140 target and site of action

SER140, an IL-1 receptor antagonist, is expected to reduce the inflammatory cascade in Type 2 Diabetes (T2D), reduce apoptosis of pancreatic β-cells and increase peripheral insulin sensitivity. In vitro and in vivo studies have confirmed that SER140 significantly inhibited IL-1β-induced TNF-α secretion in macrophages.  Furthermore, SER140 antagonized IL-1β-induced primary rat islet apoptosis, exceeding the antagonistic effect of the IL-1R protein blocker, anakinra (Kineret®).  

2.   Competitive edge

Treatment of T2D patients normally follows the mutual recommended guidelines of American Diabetes Association (ADA) and the European Association for Study of Diabetes (EASD). 

All currently available treatments for T2D are initially effective and reduce complication rates but they lack the ability to maintain glycemic control in the long term. This is due to the progressive nature of both pancreatic β-cell dysfunction and cell death and loss of peripheral insulin receptor sensitivity. Stopping the progression represents one of the highest clinical unmet needs in T2D treatment.